IMC Chicago’s Apellis Pharmaceuticals APLS Stock Holding History

IMC Chicago’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,600	Closed	-$1.39M	–	6330
2026 Q1	$1.39M	Buy	34,600 +20,000	+137%	+$431K	﹤0.01%	2935
2025 Q4	$367K	Sell	14,600 -4,300	-23%	-$101K	﹤0.01%	3680
2025 Q3	$428K	Buy	18,900 +2,200	+13%	+$51.3K	﹤0.01%	3265
2025 Q2	$289K	Buy	16,700 +6,100	+58%	+$113K	﹤0.01%	3123
2025 Q1	$232K	Buy	+10,600	New	+$293K	﹤0.01%	3015
2023 Q4	–	Sell	-52,600	Closed	-$2M	–	1804
2023 Q3	$2M	Buy	+52,600	New	+$2.31M	﹤0.01%	980

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

IMC Chicago's APLS Position: Q2 2026 in Review

IMC Chicago sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 59,232 shares — an estimated $2.38M sold.

IMC Chicago first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $2.38M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

IMC Chicago reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 59,232 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.38M.
IMC Chicago first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
IMC Chicago's Apellis Pharmaceuticals position peaked at $2.38M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.